Wisconsin Discovery Portal

Researcher: Igor Slukvin

[ printable ]
Areas of Expertise
  • Hematopoietic differentiation of human embryonic stem cells
  • Obtain engraftable in vivo hematopoietic stem cells from ES cells
  • Derive human lymphocytes, myeloid cells and dendritic cells from ES cells
  • Immune tissue engineering and immunotherapy
  • Hematopoietic cell differentiation from ES cells
  • Molecular mechanism directing human ES cells towards early hematopoietic progenitors
  • Expand ES-derived hematopoietic cells by genetic methods
  • Scalability of ES cell hematopoiesis
  • Immune-privileged properties of embryonic and fetal tissues
Web Site Igor Slukvin's Department of Pathology and Laboratory Medicine Website
Curriculum Vitae (CV)
Issued Patent(s)
  • 9,381,210 - Induced pluripotent stem cell model of chronic myeloid leukemia revealed olfactomedin 4 as a novel therapeutic target in leukemia stem cells, issued July 2016.
  • 8,846,395 - Generation of mature myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin.sup.-cd34.sup.+cd43.sup.+cd45.sup.+progenitors, issued September 2014.
  • 8,785,189 - Method of forming dendritic cells from embryonic stem cells, issued July 2014.
  • 8,158,422 - Erythroid cells producing adult-type .beta.-hemoglobin generated from human embryonic stem cells, issued April 2012.
  • 8,133,732 - Method of forming myeloid precursor cells from human embryonic stem cells, issued March 2012.
USPTO Published Applications
  • 20160194610 - Angiohematopoietic progenitor cells, published July 2016.
  • 20160186137 - Derivation of human microglia from pluripotent stem cells, published June 2016.
  • 20150175971 - Multipotent cells having mesenchymal and endothelial lineage potential, published June 2015.
  • 20150005361 - Induced pluripotent stem cell model of chronic myeloid leukemia revealed olfactomedin 4 as a novel therapeutic target in leukemia stem cells, published January 2015.
  • 20140273211 - Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions, published September 2014.
Recent Publication(s)
  • Generating human hematopoietic stem cells in vitro: Exploring endothelial to hematopoietic transition as a portal for stemness acquisition. Slukvin II. FEBS Lett. 2016 Jul 8. doi: 10.1002/1873-3468.12283. [Epub ahead of print] Review.

  • Gsk3β inhibition promotes efficient myeloid and lymphoid hematopoiesis from non-human primate-induced pluripotent stem cells. D'Souza SS, Maufort J, Kumar A, Zhang J, Smuga-Otto K, Thomson JA,Slukvin II. Stem Cell Reports. 2016 Feb 9;6(2):243-56. doi: 10.1016/j.stemcr.2015.12.010. Epub 2016 Jan 21.

  • Ccr5 disruption in induced pluripotent stem cells using crispr/cas9 provides selective resistance of immune cells to ccr5-tropic hiv-1 virus. Kang H, Minder P, Park MA, Mesquitta WT, Torbett BE, Slukvin II. Mol Ther Nucleic Acids. 2015 Dec 15;4:e268. doi: 10.1038/mtna.2015.42.

  • Nonirradiated nod,b6.scid il2rγ-/- kit(w41/w41) (nbsgw) mice support multilineage engraftment of human hematopoietic cells. McIntosh BE, Brown ME, Duffin BM, Maufort JP, Vereide DT, Slukvin II, Thomson JA. Stem Cell Reports. 2015 Feb 10;4(2):171-80. doi: 10.1016/j.stemcr.2014.12.005. Epub 2015 Jan 15.
Recent Artistic Works
  • Wisconsin National Primate Research Center
Research Tools
Research Facilities
E-mail Address [email protected]
Phone Number 608-263-0058
Current University UW–Madison
Department Pathology and Laboratory Medicine
Title Professor
Other Appointments
Address Line 1 Room 129
Address Line 2 1220 Capitol Court
City Madison
State WI
Zip Code 53715
Bachelor's Degree
Master's Degree
PhD Ph.D., Kiev Institute of Pediatrics, Ukraine, Obstetrics and Gynecology, 1987
Other Degrees M.D., Kiev Medical Institute, Ukraine, 1984
Technologies Available for Licensing Reprogrammed Stem Cell Line for Research: IISH3i-CB6

Reprogrammed Stem Cell Line for Research: IISH4i-CBT4

Method of Forming Dendritic Cells from Embryonic Stem Cells

Multipotent Lymphohematopoietic Progenitor Cells

Treating Chronic Myeloid Leukemia

Xenogen-Free Culture Medium for Stem Cells

Generating Vasculogenic Cell Populations from Human Stem Cells